Coenzyme Q10 in Pediatric Community-Acquired Pneumonia

NCT07317440 | Not Yet Recruiting

• 1 other identifier: 36264PR1169/3/25
• Study Type: interventional
• Target: 120
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this work is to assess the benefit of coenzyme Q10 supplementation, in addition to standard antibiotic and other supportive therapy, in the management of hospitalized children with community acquired pneumonia

Conditions

Community Acquired Pneumonia

Outcome Measures

Primary Outcomes (10)

• Normalization of respiratory rate

  3 days

• Normalization of temperature

  3 days

• Normalization of oxygen saturation

  3 days

• Normalization of Feeding Behavior Assessed by Oral Intake Tolerance

  Normalization of feeding refusal will be assessed by evaluating the child's ability to tolerate age-appropriate oral feeding without refusal over a 3-day observation period.

  3 days

• Serum C-Reactive Protein (CRP) Level

  Blood samples will be collected, and CRP concentration will be expressed in milligrams per liter (mg/L).

  5 days

• Serum Lactate Dehydrogenase (LDH) Level

  LDH concentration will be reported in units per liter (U/L) from venous blood samples.

  5 days

• Prognostic Nutritional Index

  5 days

• Systemic Immune-Inflammation Index

  5 days

• Serum C-Reactive Protein to Albumin Ratio (CRP/Albumin Ratio)

  The serum C-reactive protein to albumin ratio (CRP/albumin ratio) will be calculated as a single composite outcome measure using laboratory values obtained from the same blood sample.

  5 days

• Time of clinical stability

  3-5 days

Secondary Outcomes (2)

• Length of hospital stay

  10-21 days

• Number of Participants Requiring Surgical Intervention

  21-30 days

Study Arms (2)

60 children with community acquired pneumonia will receive oral coenzymeQ10

EXPERIMENTAL

Drug: oral coenzymeQ10

60 children with community acquired pneumonia with the standard pneumonia treatment.

NO INTERVENTION

Interventions

oral coenzymeQ10 DRUG

60 children with community acquired pneumonia will receive oral coenzymeQ10 in capsule form at a dose of 100-200 mg/kg/day, as adjunct therapy to the usual pneumonia treatment till the recovery of the disease.

60 children with community acquired pneumonia will receive oral coenzymeQ10

Eligibility Criteria

• Age: 2 Months - 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• All children aged 2 months -18 years with community acquired pneumonia diagnosed by signs and symptoms of CAP including; chest pain, dyspnea, tachypnea, or abnormal auscultatory findings plus focal findings on chest x ray indicating community acquired pneumonia

You may not qualify if:

• Children with immunodeficiency, chronic lung disease, malignancy, congenital lung anomalies, underlying disorder impacting respiration i.e. genetic, metabolic, neuromuscular disorders, children with CHD affecting the pulmonary blood flow.

Sponsors & Collaborators

• Tanta University: lead

Study Sites (1)

Tanta University

Tanta, Gharbia Governorate, 37515, Egypt

Location

MeSH Terms

Conditions

Community-Acquired Pneumonia

Condition Hierarchy (Ancestors)

Community-Acquired Infections; Infections; Pneumonia; Respiratory Tract Infections; Respiratory Tract Diseases

Central Study Contacts

Ahmed Elniny Lecturer of Pediatrics, MD

CONTACT

01002219783; Ahmedelniny8@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lecturer of pediatrics

Study Record Dates

• First Submitted: June 9, 2025
• First Posted: January 5, 2026
• Study Start: December 31, 2025
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): December 31, 2026
• Last Updated: January 5, 2026

Record last verified: 2025-12

Locations

EG (1)